Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?   

In short, the answer is YES—I always look for ways to reduce immunosuppression exposure over time and use the lowest effective dose required to keep a patient’s inflammatory ILD in check. I often remind myself that when these patients present with a mixture of fibrotic changes (e.g., tra...